Pharmala Biotech Holdings Inc. (CSE:MDMA)

Canada flag Canada · Delayed Price · Currency is CAD
0.0850
-0.0050 (-5.56%)
Dec 5, 2025, 3:59 PM EST
-73.85%
Market Cap 9.78M
Revenue (ttm) 420.81K
Net Income (ttm) -2.04M
Shares Out 108.62M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 84,787
Average Volume 142,147
Open 0.0900
Previous Close 0.0900
Day's Range 0.0850 - 0.0900
52-Week Range 0.0850 - 0.3300
Beta 0.77
RSI 34.74
Earnings Date Dec 19, 2025

About Pharmala Biotech Holdings

Pharmala Biotech Holdings Inc., doing business as PharmAla, a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Nicholas Kadysh
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol MDMA
Full Company Profile

Financial Performance

In 2024, Pharmala Biotech Holdings's revenue was 1.04 million, an increase of 94.60% compared to the previous year's 532,003. Losses were -823,596, 5.61% more than in 2023.

Financial Statements

News

There is no news available yet.